ArticleInternational journal of ophthalmology2025
Mapping key trends, relationships, and molecular pathways for neuroprotection in glaucoma: a bibliometric approach.
Article in International journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurotoxic effects of dietary glutamate in glaucoma and potential nutritional and pharmacological therapies: a scoping review.International ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma, a degenerative optic neuropathy, causes retinal ganglion cell (RGC) apoptosis and irreversible vision loss. Current therapies often fail to stop disease progression despite lowering intraocular pressure, the main risk factor. Thus, neuroprotective strategies have gained interest. We performed a bibliometric analysis to determine global publishing trends and relationships among prolific authors, publications, institutions, funding agencies, and journals. We also analyzed author keywords to identify research hotspots in glaucoma neuroprotection. Further, based on keyword analysis, we reviewed most recent literature to understand mechanistic pathways underlying glaucoma-related pathophysiological responses leading to RGC loss. Bibliographic data were sourced from Scopus. Basic bibliographic features were characterized using Scopus's functions. VOSviewer was used for mapping and visualizing bibliometric networks. The analysis included trends in publications since 2000, the most prolific countries, institutions, authors, and the strength of their linkages. A significant increase in publication output over the past two decades was noted. The United States leads in funding support, research output, and citation links, followed by China and the UK. Among the top 10 most cited authors, three are from Japanese institutions. Keyword analysis shows a focus on molecular targets related to ischemia, excitotoxicity, inflammation, and oxidative stress, with fewer emerging drug candidates and limited clinical trials. Based on the most recent literature, emerging molecular targets underlying these key pathophysiological mechanisms are summarized. In conclusion, while pathophysiology and molecular mechanisms are the current focus, there is not much progress in developing new drug candidates and conducting clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.